Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Monopar Therapeutics Inc.NASDAQ: MNPR

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $287.14K (cash outflow) fell 62.8% year over year, behind the +4647.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -36.0% a year.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -62.8% toward the trailing-twelve-month pace of +4647.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$287.14K-138.9% QoQ
Last fiscal yearDec 2025
$388.22K-23.4% YoY
LTMMar 2026
$872.05K+4647.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.8%——
1 year-23.4%——
3-year CAGR-36.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
388.22K USD
Year-over-year change
-23.4%
4-year CAGR
-1.0%

Accounts Payables vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4647.1% is the highest of 10, against a peer median of -91.2%.
  • Over three fiscal years its annual growth of -36.0% compares with a peer median of -27.1%.
MNPR Competitors
Accounts Payables for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$45.36M USD+357.1%—17.1%
ADCTADC Therapeutics S.A.LTM Mar 2026$10.3M USD-925.0%—13.0%
XNCRXencor, Inc.LTM Jun 2026$6.13M USD-229.5%+0.3%5.8%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M USD-48.2%-70.5%1.5%
BCYCBicycle Therapeutics plcLTM Mar 2026$1.2M USD-69.6%—1.9%
IMNMImmunome, Inc.LTM Sep 2026$1.13M USD-147.6%+138.3%—
MNPRMonopar Therapeutics Inc.LTM Mar 2026$872.05K USD+4647.1%-36.0%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$721K USD+149.2%—2.1%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$671K USD-192.8%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$233K USD-91.2%-54.6%—
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
Peer median (excluding MNPR) —-91.2%-27.1%2.1%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.47M1.64M1.9M1.14M4.84M
Change in Working Capital317.77K1.65M(1.35M)3.49M(2.61M)
Accounts Receivables00000
Inventory00000
Accounts Payables403.97K1.48M(1.33M)506.79K388.22K
Other Working Capital(86.2K)167.52K(20.41K)2.98M(2.99M)
Other Non-Cash Items0004.55M(716.46K)
Operating Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)
Capital Expenditures10000
Acquisitions (Net)00000
Purchases of Investments0(4.92M)(7.88M)(15.32M)(87.15M)
Sales of Investments0012.81M985.73K23.7M
Other Investing Activities00000
Investing Cash Flow0(4.92M)4.93M(14.34M)(63.45M)
Debt Repayment00000
Common Stock Issued10.93M109.34K2.07M59.4M127.71M
Common Stock Repurchased0000(35M)
Dividends Paid00000
Other Financing Activities(45.78K)(76.46K)(46.97K)(104.14K)(1.13M)
Financing Cash Flow10.88M32.87K2.03M59.29M91.57M
Effect of Forex Changes4.62K(3.48K)(16.8K)49497.27K
Net Change in Cash3.57M(12.12M)(920.11K)38.55M16.02M
Free Cash Flow(7.32M)(7.23M)(7.86M)(6.4M)(12.2M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.